Publications by authors named "Randall Kaye"

Claim this Profile
B
Bexicaserin for the treatment of seizures in developmental and epileptic encephalopathies: A phase 1b/2a trial (PACIFIC).
Dennis J Dlugos, Ingrid E Scheffer, Jacqueline A French, David G Vossler, Chad Orevillo, Randall Kaye

Epilepsia· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double-Blind, Placebo-Controlled Study.
Jonathan Williams, Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Randall Kaye

Clin Pharmacol Drug Dev· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Bexicaserin in Healthy Participants: A First-in-Human Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Escalation Phase 1 Study.
Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Randall Kaye

Clin Pharmacol Drug Dev· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RESUME-1: a Phase III study of tolperisone in the treatment of painful, acute muscle spasms of the back.
Sanam Ara Vaughan, Kayla Torres, Randall Kaye

Pain Manag· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolperisone for the Treatment of Acute Muscle Spasm of the Back: Results from the Dose-Ranging Phase 2 STAR Study (NCT03802565).
Srinivas Nalamachu, Joseph Pergolizzi, Randall Kaye

J Pain Res· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An assessment of the centrally acting muscle relaxant tolperisone on driving ability and cognitive effects compared to placebo and cyclobenzaprine.
Judy Caron, Randall Kaye, Thomas Wessel, Amy Halseth, Gary Kay

J Clin Pharm Ther· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PRISM: a novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditions.
Benjamin Rix Brooks, David Crumpacker, Jonathan Fellus, Daniel Kantor, Randall E Kaye

PLoS One· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pseudobulbar affect: an under-recognized and under-treated neurological disorder.
Susan S Work, Jennifer A Colamonico, Walter G Bradley, Randall E Kaye

Adv Ther· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect.
Erik P Pioro, Benjamin Rix Brooks, Jeffrey Cummings, Randolph Schiffer, Ronald A Thisted, Randall Kaye

Ann Neurol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis